Compare TRI & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRI | KVUE |
|---|---|---|
| Founded | 1851 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Specialty Chemicals |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 36.6B |
| IPO Year | 2002 | 2023 |
| Metric | TRI | KVUE |
|---|---|---|
| Price | $105.56 | $18.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $164.55 | $19.64 |
| AVG Volume (30 Days) | 3.8M | ★ 48.2M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | 2.45% | ★ 4.39% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $8.86 | $4.07 |
| Revenue Next Year | $7.86 | $2.92 |
| P/E Ratio | $25.72 | ★ $24.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.71 | $14.02 |
| 52 Week High | $218.40 | $25.17 |
| Indicator | TRI | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 46.34 |
| Support Level | $79.71 | $16.73 |
| Resistance Level | $135.03 | $18.97 |
| Average True Range (ATR) | 5.16 | 0.39 |
| MACD | 3.36 | -0.06 |
| Stochastic Oscillator | 99.46 | 12.70 |
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.